Big Pharma has been slowly but surely warming up to the potential of digital therapeutics, as evidenced by Sanofi inking a deal two months ago with DarioHealth. And on Thursday, another Big Pharma will take a look at the space in what it deems as simply the next step in an ongoing partnership.

Icelandic biotech Sidekick Health announced the launch of its digital therapeutics product specifically geared for atopic dermatitis Thursday alongside Pfizer, its Big Pharma partner who collaborated on the indication. CMO and co-founder Saemundur “Sam” Oddsson told Endpoints News that this is not the first time that Pfizer and Sidekick Health have worked together — in fact, it is the fourth digital therapeutics product that the pair have co-launched.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

We will be off Monday in observance of Memorial Day — and when we get back, it will be a straight march to ASCO, BIO and more. Enjoy the (long) weekend!

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Rich Horgan’s quest to create a custom gene therapy for his brother, Terry, ended in tragedy. But Horgan doesn’t believe it’s the end of the story.

Terry, a 27-year-old patient with Duchenne muscular dystrophy, died last October just eight days after receiving the therapy in a clinical trial in which he was the only participant. The case raised questions about the safety of certain gene therapies and what would happen to other drug programs under a nonprofit that Horgan created, called Cure Rare Disease.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Even in a down year for much of the biopharma market, 20 CEOs brought in pay packages valued at more than $20 million, an Endpoints News analysis found.

Endpoints collected data on more than 350 CEO compensation packages, covering a wide range of pharma, biotech, and life sciences companies. All told, the 20 largest earners made over $725 million in 2022 — an average package of $36.4 million. Three brought in paydays over $50 million, and one CEO broke the $100 million mark.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

This year’s list of 20 biotech leaders under the age of 40 includes a huge range of ambitions. Some of our honorees are planning to create the next big drug giant. Others are pushing the bounds of AI. One is working to revolutionize TB testing. All are compelling talents who are still young in age, but already far along in achievement.

And, as in years past, we went over. The 20 are actually 22 because of two double profiles that reflect how important teamwork is in the industry. As one of our honorees, Joe Illingworth of DJS Antibodies, told me in our interview, “It takes a village to raise a biotech.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

The FDA on Friday approved Lexicon’s heart failure drug sotagliflozin following a string of setbacks for the pharma company, including an FDA rejection in diabetes and the loss of a development deal with Sanofi.

The dual SGLT1 and SGLT2 inhibitor will be marketed as Inpefa and is a once-daily tablet. It’s been approved to reduce the risk of cardiovascular death and heart failure-related hospitalization or urgent visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The label spans the range of left ventricular ejection fraction, including preserved ejection fraction and reduced ejection fraction, as well as patients with or without diabetes, Lexicon said Friday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Firefighters are more likely than the general population to be diagnosed with bladder cancer, but it’s not widely known. So Astellas and Seagen are raising awareness of the issue as part of their ongoing “Let’s Talk Bladder Cancer” campaign.

Social media posts on Twitter, Facebook and LinkedIn during this month’s Bladder Cancer Awareness month link to a sponsored article in Firehouse magazine that talks about the increased risks of bladder cancer.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Genentech is reprising its high-style fashion show for spinal muscular atrophy awareness with an encore run next month.

The original “Double Take” show featured models who are living with SMA, and some family members, wearing custom-designed adaptive clothing, and debuted last fall around New York Fashion Week. The new encore show will debut at the annual Cure SMA conference in Orlando on June 29 with nine of the original models walking or rolling the runway.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN